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We undertook a meta-analysis of six Crohn’s disease (CD) genome-wide association studies
(GWAS) comprising 6,333 cases and 15,056 controls, and followed up the top association
signals in 15,694 cases, 14,026 controls and 414 parent/offspring trios. Thirty new
susceptibility loci meeting genome-wide significance (P-value <5×10−8) were identified. A
series of in silico analyses highlighted particular genes within these loci and, together with
manual curation, implicated functionally interesting candidate genes including SMAD3,
ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3a, DENND1B, BACH2 and TAGAP.
Combined with previously confirmed loci, the results described here identify a total of 71
distinct loci with genome-wide significant evidence for association with Crohn’s disease.
Crohn’s disease (OMIM #266600) results from the interaction of environmental factors,
including the intestinal microbiota, with host immune mechanisms in genetically susceptible
individuals. Along with ulcerative colitis (UC), it is one of the main subphenotypes of
inflammatory bowel disease (IBD). GWAS have highlighted key CD pathogenic
mechanisms, including autophagy and Th17 pathways. A meta-analysis of these early scans
implicated 32 susceptibility loci, but only accounted for 20% of the genetic contribution to
disease risk - suggesting that more loci await discovery1. Recognizing that an increased
sample size would be required to detect these, we have expanded the International IBD
Genetics Consortium (IIBDGC), approximately doubling the discovery panel size in
comparison with the first meta-analysis.
The discovery panel for the current study comprised 6,333 CD subjects and 15,056 controls,
all of European descent, with data derived from six index GWAS studies (for overview see
Supplementary Table 1)2-6. Imputation using HapMap3 reference data allowed us to test for
association at 953,241 autosomal SNPs. Our discovery panel had 80% power to detect
variants conferring odds ratios ≥1.18 at the genome-wide significance level of P<5×10−8,
assuming a minor allele frequency ≥20% in healthy controls. Under the same conditions, the
sample size of our original meta-analysis had only 11% power1.
A quantile-quantile plot of the primary meta-statistic, using single-SNP Z-scores combined
across all sample sets, showed a marked excess of significant associations (Supplementary
Figure 1). A total of 2,024 SNPs within 107 distinct genomic loci, including all previously
defined significant hits from our earlier meta-analysis, demonstrated association with P-
values <10−5. A Manhattan plot is shown in Supplementary Figure 2. 51 of the regions,
representing new loci associated at P<5×10−6, were followed up by genotyping the most
significant SNPs in an independent panel of 15,694 CD cases, 14,026 controls and 414
parent/offspring trios (see Table 1 and Supplementary Table 2).
Variants within 30 distinct new loci met a genome-wide significance threshold of P<5×10−8
for association with CD in the combined discovery plus replication panel, with at least
nominal association in the replication panel (see Table 1). Two additional loci,
encompassing the CARD9 and IL18RAP genes, had previously been reported as associated
with CD in a candidate gene study7 and were here both replicated and confirmed at
P<5×10−8. Five loci were identified at genome-wide significance in GWAS studies
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published subsequent to our replication experiment being designed. One, the FUT2 locus,
was from a recent adult CD GWAS6. Four more (ZMIZ1, IL27 at 16p11, 19q13 and 22q12)
were identified in a pediatric IBD population5, these replicating here in our current sample
set. Two further loci had produced “suggestive” evidence of association with replication in
our earlier study1. Here, these clearly exceeded the genome-wide significance threshold in
the meta-analysis alone and, given the previous replication evidence, were not followed up
further (see Table 1). Thus cumulatively, 39 additional loci can now be added to the 32
confirmed CD susceptibility loci identified at the time of the Barrett et al. study. We did not
observe statistically significant heterogeneity of the odds ratios (Breslow Day test P-value
<0.05 after Bonferroni correction; Supplementary Table 4) between the panels from our 15
different countries (Supplementary Tables 1 and 2) for any of the 71 loci. Nor was any
evidence of interaction between the associated loci observed (Supplementary Figure 3).
Regional association plots of all 71 susceptibility loci including the underlying genes are
shown in detail in Supplementary Figure 4, and complete genotype data including odds
ratios and allele frequencies are shown in Supplementary Tables 3 and 4. Five loci had
evidence for more than one independently associated variant (Table 1). While 6 of the 30
novel regions contain just a single gene, which is thereby strongly implicated in CD
pathogenesis (e.g. SMAD3, NDFIP1 and BACH2), 22 include more than one gene within
the associated interval (Table 1; two regions without any gene or gene prediction). We thus
applied additional in silico analyses to refine the list of functional candidate genes further.
These were:
1. Interrogation of a publicly available expression quantitative trait loci (eQTL)
database8. These analyses identified genes for which expression correlates with
genotype at our most associated SNP (see Supplementary Results).
2. Use of 1000 Genomes Project Pilot sequence data and HapMap3 to identify genes
containing non-synonymous variants in strong LD (r2>0.5) with the focal SNP
within each region (for details on coding SNP see Supplementary Table 5).
3. Use of GRAIL9, to identify non-random and evidence-based connectivity between
the genes in the 71 confirmed CD loci. Specifically, GRAIL evaluates each gene in
a CD-associated locus for non-random correlation with genes in the other 70 loci
via word-usage in PubMed abstracts related to the gene (see Figure 1).
Summary results of these analyses are shown in the rightmost column of Table 1. The
highlighted genes are described briefly in Box 1, as are genes that constitute particularly
noteworthy candidates from intervals containing one or few genes. While we believe that
these evidence-based approaches are helpful in identifying likely functional candidates, in
some instances the different techniques highlight different genes. This reflects uncertainty as
to which is causal, and highlights the need for functional studies.
30 new signals were identified here beyond those described in the earlier meta-analysis1 and
other subsequent publications. The new associations were driven primarily by increased
power arising from the expanded sample size rather than improved imputation, as more than
two-thirds of the novel loci identified here have good proxies (r2>0.8) on both earlier
generation arrays (Illumina 300K and Affymetrix 500k Set). Extending this argument
beyond the current analysis, it seems likely that many more loci of modest effect size still
await discovery.
For many of the novel loci, associations have been reported previously in other complex
diseases, comprising mostly chronic inflammatory disorders (Table 1). Such diseases can
cluster both within families and individuals, reflecting shared genetic risk factors. For
example, IBD and ankylosing spondylitis can co-segregate and both are associated with
Franke et al. Page 4
Nat Genet. Author manuscript; available in PMC 2012 March 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
IL23R2,10 and TNFSF1511,12. The IL10 locus was previously associated with UC13 and was
identified as a novel CD locus in the present study. Thus IL10 is a generic IBD locus, which
is a functionally intuitive finding of potential therapeutic significance.
For loci previously associated with other inflammatory diseases the direction of effect in CD
is usually the same, but in five cases the risk allele for one disease appears to be protective
in another disease (see arrow symbol in “Reported association” column in Table 1). In most
such instances, functional annotation suggests modulation of T cell and other immune
pathways. Indeed, GRAIL highlights a number of such genes. These inverse associations
may reflect overlap in the pathways by which the host regulates effector functions in defense
and regulatory functions in self-tolerance. This is a delicate balance and, in the face of
competing requirements, selection pressures may have conferred advantage for divergent
alleles in a cell- and environmentally dependent manner.
The associated SNP rs281379 at 19q13, recently also identified by McGovern et al.6 is
highly correlated (r2>0.80) with a common nonsense variant (rs601338 also known as
G428A or W142X) at FUT2. This is classically referred to as the non-secretor variant, as
individuals homozygous for this null-allele do not secrete blood group antigens at epithelial
surfaces. Recently, non-secretors were identified as having near-complete protection from
symptomatic GII.4 norovirus infection14 and the same null allele is identified here as a CD
risk factor. This suggests one potential elusive link between infection and immune-mediated
disease.
In contrast to the implication of coding variation in the FUT2 gene, our previous data
demonstrated that most CD-associated SNPs were not in LD with coding polymorphisms1,
suggesting that regulatory effects are likely to be a more common mechanism of disease
susceptibility. Providing further direct evidence for this, a number of new eQTL effects were
identified here (see Table 1 and Supplementary Results Section) – notably including
CARD9 (LOD=12.4), ERAP2 (LOD=47.2) and TNFSF11 (RANKL) (LOD=5.9). The latter
maps adjacent to but outside the associated recombination interval, suggesting another
potential long-range cis-regulatory effect as previously described for PTGER4 in CD4.
RANKL has pleiotropic immunological effects and also stimulates osteoclast activity. This
finding may be relevant to the osteoporosis clinically associated with CD.
Given the importance of regulatory effects, it is intriguing that variants within the gene
encoding a key mediator of epigenetic regulation, DNA methyltransferase 3a (DNMT3A),
should be associated with CD. By inducing transcriptional silencing, DNMT3a is known to
play an important role in immunoregulation. For example, it methylates IL-4 and IFN-γ
promoters following T cell receptor stimulation, hence regulating T cell polarization15, and
induces dynamic regulation of TNF-α transcription following lipopolysaccharide exposure
in leukocytes16. Genetically determined alterations in DNMT3a activity could thus have far-
reaching effects.
The 32 loci described up to 2008 explained approximately 20% of CD heritability. Adding
the 39 loci described since increases the proportion of heritability explained to just 23.2%.
This pattern of common alleles, explaining a logarithmically decreasing fraction of
heritability (Figure 2), is consistent with a recent model of effect size distribution17, which
predicted (based on the previous CD meta-analysis) that our current sample size would
likely identify 48 new loci. Furthermore, it is likely that more high-frequency CD risk alleles
of even smaller effect size remain unidentified: The same model predicts that 140 loci would
be identified by a sample size of 50,000, but these would explain only a few more percent of
CD heritability. It is clear, therefore, that larger GWAS alone will not explain all of the
missing heritability in CD.
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One key shortcoming of our current model of heritability explained by these loci is a direct
consequence of the extent to which GWAS tag SNPs are often imperfect proxies for causal
alleles, and thus substantially underestimate the true attributable risk. For example, the best
tag SNP at the NOD2 locus in our meta-analysis appears to explain just 0.8% of genetic
variance, whereas the three NOD2 coding mutations themselves account for 5%. If an
analogous situation applies to even a small fraction of the other 70 CD susceptibility loci,
the proportion of overall heritability explained will increase significantly. Indeed, one study
of LD between tag SNPs and causal variants in the heritability of human height18 suggests
that this effect might double the total fraction of heritability explained by GWAS SNPs.
Coding variants identified here from the 1000 Genomes Project which are in strong LD with
the focal SNPs in several of our regions (see Supplementary Table 4) thus now require direct
assessment in order to explore this possibility.
Other factors will also account for the heritability gap, including uncertain epidemiological
estimates of disease prevalence and total heritability, as well as our observation that several
of the new regions contain more than one independent risk allele. The likelihood is that
many more such effects will be identified. Indeed, detailed future analyses will play a key
role in helping us to understand the absolute contribution of common causal alleles, as well
as identifying less common variants and rare (even family-specific) mutations. By contrast,
our lack of evidence for epistasis among the loci described here suggests that non-additive
interactions among common risk alleles do not play an important role in the genetic
architecture of CD.
The current study has approximately doubled the number of confirmed CD susceptibility
loci. For many of these loci we have identified potentially causal genes, accepting that
confirmation of their role must await detailed fine mapping, expression and functional
studies. While the alleles detected only modestly affect disease risk, they continue to
enhance our understanding of the genetic etiology of CD. Analysis for evidence of sub-
phenotype associations represents an important future goal for the consortium. Thus, we are
working towards sharing of detailed genotype and clinical data to allow this. In the
meantime, extensive resequencing, together with large-scale fine mapping exercises using
custom array-based technologies, are already underway and will further elucidate the
pathogenic mechanisms of IBD.
Supplementary Material
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Box 1
Noteworthy genes within loci newly implicated in Crohn’s disease pathogenesis. N.B.
Although we highlight these as interesting genes, we do not yet have data to confirm
causality
▪ VAMP3 (1p36) encodes vesicle-associated membrane protein 3: following
bacterial stimulation of TNF-α production within macrophages, VAMP3 interacts
with SNARE proteins first on the trans-Golgi network, where TNF-alpha is taken up,
and then on the cell membrane, where TNF-α is released19. VAMP3 also plays a
role in cell migration and adhesion, by trafficking molecules such as beta1 integrin
to the cell surface, and has been implicated in autophagy20.
▪ MUC1/SCAMP3 (1q22) MUC1 encodes a key constituent of mucus, which is the
physical barrier that protects the intestinal epithelium from gut bacteria. MUC1
overexpression and hypoglycosylation have been reported in IBD21 and Muc1
knockout mice exhibit increased small intestinal damage after C. jejuni infection22.
Secretory carrier membrane protein 3 (SCAMP3) regulates EGFR trafficking within
endosomal membranes23. It is manipulated by intracellular salmonellae to acquire
nutrients and influence host immune responses24.
▪ DENND1B (1q31) has been recently associated with asthma25, and is expressed in
dendritic and effector memory T cells. Among other functions it modulates
inflammatory signaling pathways, including Th1-Th2 cytokines, through repression
of TNFR1 signaling.
▪ IL10 (1q32): association with CD follows its recent implication in UC13 and
reporting of mutations in the IL10 receptors in extreme CD of infancy26. Known to
inhibit synthesis of pro-inflammatory cytokines within macrophages and Th1 cells,
IL10 also suppresses antigen presenting cell activity. Knockdown of IL10 in mice
presents one of the best animal models of IBD.
▪ DNMT3A (2p23): DNA methyltransferase 3a is one of three key methyltransferase
genes in humans - effecting epigenetic regulation of gene transcription by
methylating cytosine residues within CpG islands. Among many other roles this is
known to determine dynamic regulation of both adaptive and innate immune
mechanisms15,16.
▪ GCKR (2p23) encodes an inhibitor of glucokinase, with the focal SNPs at this
locus also correlating with both fibrinogen and CRP levels27.
▪ THADA (2p21) is expressed in small intestine and appears to encode a death
receptor-interacting protein suggesting an apoptotic function28.
▪ ERAP2 (5q15): regulated by NF-κB, this gene encodes one of two human
endoplasmic reticulum aminopeptidases, which work in concert to trim peptides for
presentation on MHC class I and hence critically affect antigen presentation to T
cells29. Ankylosing spondylitis is associated with this locus but with a different
pattern of associated variants30. Given the close clinical relationship between CD
and AS, and the strong association of HLA-B27 with the latter but not the former,
the divergent association of these closely related molecules is intriguing and will
refocus interest on the MHC class I associations in CD.
▪ NDFIP1 (5q31): Nedd4 family interacting protein 1 is a membrane protein
involved in maintenance of the Golgi complex31. It is important for protein
trafficking via exosomes and may play a role in rapid sequestration and removal of
proteins during stress32.
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▪ CPEB4 (5q35) is a regulator of protein translation and cell division, and a
transcriptional target of RORγt. Mouse work suggests that the product of CPEB4 is
the effector by which RORγt (a key determinant of Th17 cell differentiation)
inhibits proliferation of thymocytes33.
▪ TAGAP (6q25): T-cell Activation GTPase-Activating Protein, associated with
multiple autoimmune diseases, was originally identified through its involvement in
human T cell activation and co-regulation with IL-234.
▪ IL2RA (10p15) encodes part of the IL2 receptor complex, thus mediating IL2
signalling in host defence and regulating response to autoantigens by Tregs. The
associated variants correlate with differential expression of IL2RA (CD25) on CD4+
naïve and memory T cells35 possibly affecting Foxp3+ Treg homeostasis36.
▪ FADS 2 (11q12): fatty acid desaturase 2 is predominantly located in the
endoplasmic reticulum. Fads2 knockout mice develop duodenal and ileocecal
ulceration37.
▪ TNFSF11 (13q14) (synonyms RANKL - receptor activator of nuclear factor kappa
B; ODF osteoclast differentiation factor) encodes a member of the TNF cytokine
family. RANKL stimulation of dendritic cells leads to proliferation of naive T cells
and inducible Tregs38; it also regulates osteoclast activity / bone loss. Previous
studies have demonstrated increased plasma levels in Crohn’s disease39.
▪ SMAD3 (15q22): phosphorylated following TGF-β signalling through its receptor,
the SMAD3 protein complexes with SMAD4 and is then translocated to the nucleus
to modulate target gene expression. SMAD3 plays a key role in the TGF-β-mediated
induction of Foxp3+ regulatory T cells40, with SMAD3 deficiency reciprocally
enhancing Th17. Reduced SMAD3 phosphorylation has been observed in IBD, and
may impair the immunosuppressive effect of TGF-β.
▪ TYK2 (19p13) encodes tyrosine kinase 2, a member of the JAK-signal transduction
family. It is involved in cytokine signaling by IFN-γ, IL-12 and IL-23 among others
– hence affecting Th1 and Th17 lineage development. TYK2 also plays an important
role in TLR-mediated responses in dendritic cells, including IL-12 and IL-23
production, and TYK2 mutations predispose to opportunistic infection41.
▪ FUT2 (19q13) encodes alpha-(1,2)fucosyltransferase which regulates expression
of the Lewis AB0(H) histo-blood group antigens on the surface of epithelial cells
and in body fluids. Strongly associated with Norovirus infection, also with
Helicobacter pylori infection and serum vitamin B12 levels14,42.
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Figure 1. Gene Relationships Across Implicated Loci (GRAIL) pathway analysis
Links between genes at 23 of 71 Crohn’s disease associated loci which scored P<0.01 using
GRAIL. Specifically, of the 71 CD-associated SNPs, 69 are in LD intervals containing or
within 50 kb of at least one gene. In total, there are 355 genes implicated by proximity to
these 69 SNPs. Each observed CD-association was scored with GRAIL, which takes all
genes mapping within CD-associated intervals and evaluates for each whether it is non-
randomly linked to the other genes, via word-usage in PubMed abstracts. 23 SNPs shown in
the outer circle are P<0.01 hits - indicating that the regions which they tag contain genes
which are more significantly linked to genes in the other 68 regions than expected by chance
at that level. The lines between genes represent individually significant connections that
contribute to the positive signal, with thickness of lines inversely proportional to the
probability a literature-based connection would be seen by chance.
To accurately assess the statistical significance of this set of connections, we conducted
simulations where we selected 1000 sets of 69 SNPs implicating in total 355 genes ±18 (5%)
(selecting the SNPs randomly and using rejection sampling - only taking lists that implicated
the same number of genes). Each of those 1000 sets were scored with GRAIL. The mean
number of P<0.01 hits in a simulated list was 0.91 with a range in the 1000 sets from 0 to
11, suggesting that the likelihood of observing 23 hits with P<0.01 is far less than 0.1%.
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Figure 2. Cumulative fraction of genetic variance explained by 71 CD loci
Cumulative fraction of genetic variance explained by the 71 CD loci reported here, ordered
from largest to smallest individual contribution. Black points were identified pre-GWAS,
green in first generation GWAS, blue in an earlier meta-analysis and cyan in this analysis.
Inset shows a logarithmic fit to these data extrapolated to an extreme scenario where 20,000
independent common alleles are associated with disease. Even in this situation less than half
of the genetic variance would be explained. This demonstrates that other types of effect (e.g.
less common and rare alleles with higher penetrance) must also exist.
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